Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and sex toys.
Popular Articles

Kidney Atlas In 3-D Created For Researchers And Physicians
Renal diseases shall be diagnosed earlier and treated more successfully in the future. Towards this aim, researchers from nine European countries*, coordinated by the Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have been working for the past four-and-a half years to create a three-dimensional virtual "Kidney Atlas". It incorporates the latest research findings on the development and diseases of the kidney. The Kidney Atlas was part of the European Renal Genome Project (EuReGene), which the European Union (EU) funded with more than 10 million euros. At the conclusion of the project, the Kidney Atlas was presented at MDC during a two-day symposium from May 15-16, 2009, which was attended by approximately 100 researchers.
buy viagra
Study Suggests H1N1 Virus More Dangerous Than Suspected
A new, highly detailed study of the H1N1 flu virus shows that
News of the day
Breast Cancer Research Highlights From The American Association Of Physicists In Medicine Meeting In Anaheim, July 26-30
Half of all Americans will be diagnosed at some point in their lives with cancer, the number two killer in the United States. One of the most common types, especially among women, is breast cancer. According to the National Cancer Institute, 192,370 women will be diagnosed with breast cancer in 2009, and more than 40,000 women will die from the disease this year alone.
Nutrition

UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®. "Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon"s chairman and chief executive officer. About CIMZIA® Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn"s disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia® was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn"s disease who have not responded adequately to conventional treatment in September 2007. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A. Enzon Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009